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cancer, the median survival was 4,1 years. The potential to improve 
survival coupled with the fact that most second primary lung cancers 
are asymptomatic at the time of diagnosis suggest that careful post-
operative surveillance of patients with early stage non-small cell lung 
cancer is warranted. 
In patients with synchronous cancers located in different lungs, a staged 
bilateral thoracotomy at an interval of 4 to 6 weeks is recommended. 
It seems logical to start at the side with the higher stage of the disease. 
When a complete resection was performed, the contralateral side can be 
explored and eventually resected. 
Conclusion
The management of patients in whom a second primary lung cancer 
develops remains a challenging problem. However, there appears to be 
a beneﬁt from surgical resection in well selected patients. 
Prognosis after resection of a synchronous tumour is substantially 
lower compared to prognosis after resection of a metachronous lesion. 
An exception are satellite nodules in the same lobe which have a better 
prognosis after resection.
Because accurate differentiation of synchronous or metachronous 
tumours from intrapulmonary metastasis or recurrent lung cancer is not 
always clinically possible, patients with adequate pulmonary and physi-
ologic reserve should undergo surgical resection of the second lesions 
after careful staging. 
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Owing to the advent of reﬁned chest CT images with higher resolution 
and CT screening programs, smaller lung cancers are being discovered 
in asymptomatic patients. Most of them are more often found on a 
low-dose CT images, and they tend to have characteristic appearance 
on high-resolution CT scan as ground glass opacity (GGO), a focal 
intermediate/mild increase in the CT density. Of course, the screening 
program is still picking up the more solid tumors with/without lymph 
node involvement, the percentage of GGO or GGO-like lesions is 
obviously increased in low-dose CT screening era. These GGO tumors 
are pathologically characterized by the morphology of non-/minimally 
invasive form of well-differentiated adenocarcinoma termed as bron-
chioloalveolar carcinoma (BAC) of the non-mucinous type. 
The superb prognosis of these GGO-BAC tumors is being recognized 
in the surgical community. Although the gold standard operation for 
peripheral lung cancer has been lobectomy with lymph node sampling/
dissection, the revision is thought to be necessary, especially for these 
screen-detected GGO-BAC tumors. The possibility of limited resection 
such as segmentectomy/wedge resection seems to be realistic. Enough 
number of institutional reports describing the equivalent surgical 
outcome by limited resection have been accumulated. Therefore, the 
randomized phase III trial between lobectomy and limited resection is 
being planned both in US and Japan in a non-inferiority design setting. 
The results of these studies might be applied in the management of 
screen-detected, small-sized tumors in the near future.
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Approximately 40,000 patients / year are diagnosed with Stage III 
NSCLC. The cure rate with surgery or radiation therapy alone is less 
than 10%. There is signiﬁcant local failure with bimodality treatment. 
Treatments include concurrent chemoradiation or chemotherapy fol-
lowed by surgery. Trimodality therapy is both attractive and feasible. 
We have results from several trials available including SWOG 8805 
(stage IIIA & IIIB), INT 0160 (Pancoast ) and radiation therapy limited 
to 45 Gy. 
Current protocols studying the importance of mediastinal lymph node 
clearance are SWOG 8805; Brigham & Womens (Bueno et al., 2000); 
and CALGB 8935. The importance of pathologic complete response 
was studied by INT 0139. The University of Maryland study found 
high-dose radiation treatments to be attractive and feasible.
Residual disease is frequently present after chemoradiotherapy. This 
viable tumor may be the only disease present and resection may lead to 
cure. The incidence of local recurrence is signiﬁcant. Actual experience 
conﬁrms these assumptions. Dillman et al., in CALGB #8433î found 
median survival improved with chemotherapy. Using radiation therapy 
alone median survival was 9.7 months. Chemotherapy and radiation re-
sulted in median survival of 13.8 months. With OS improved at 7 years, 
6% with radiation alone and 13% with chemotherapy and radiation. 
(Furuse et al. J Clin Oncol 17:2692-99, 1999).
Trimodality was studied using PE x 2 cycles with XRT (45Gy) Fol-
lowed by Surgical resection in 126 Pathologic IIIa (N2) =60%, and 
pathologic IIIb = 40%. 3 year survival for IIIa = 27% and IIIb was 
24%. 5 year survival was 23% vs 21%. Pathologic complete response 
was 21% and microscopic foci were present only in 37%. A major 
path response was seen in 58%. Patients with lymph node involvement 
showed an improved survival. Grade 4 toxicity was evident in13%; 
Mortality rate was 6%. The brain was the major site of relapse in 40%; 
the sole site in 10%. INT0139 was a phase III Comparison of Chemo-
radiotherapy vs Chemoradiotherapy followed by Surgery in IIIa (N2) 
